drugset / Trial / NCT04605484

Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK Viremia

NCT04605484 ↗

Phase 2 Completed 61 enrolled AlloVir
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare Posoleucel (formerly known as ALVR105; Viralym-M) to placebo in kidney transplant recipients who have high or low levels of BK virus in their blood.

Timeline

Start
2021-03-22
Primary completion
2022-10-20
Completion
2022-10-20

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Posoleucel Cell therapy — Other